Reversal of High Fat Diet-Induced Obesity, Systemic Inflammation, and Astrogliosis by the NLRP3 Inflammasome Inhibitors NT-0249 and NT-0796Peter Thornton, Alan P. Watt, Valérie Reader et al.|Journal of Pharmacology and Experimental Therapeutics|2024Cited by 51
Discovery and Optimization of Triazolopyrimidinone Derivatives as Selective NLRP3 Inflammasome InhibitorsDavid Harrison, Alan P. Watt, M. Katharine Holloway et al.|ACS Medicinal Chemistry Letters|2022Cited by 23
Target Cell Activation of a Structurally Novel NOD-Like Receptor Pyrin Domain-Containing Protein 3 Inhibitor NT-0796 Enhances PotencyPamela J. Smolak, Christopher A. Gabel, MyTrang Nguyen et al.|Journal of Pharmacology and Experimental Therapeutics|2024Cited by 13
Pharmacological Analysis of NLRP3 Inflammasome Inhibitor Sodium [(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)carbamoyl][(1-methyl-1<i>H</i>-pyrazol-4-yl)({[(2<i>S</i>)-oxolan-2-yl]methyl})sulfamoyl]azanide in Cellular and Mouse Models of Inflammation Provides a Translational FrameworkJohn R. Doedens, Christopher A. Gabel, Pamela J. Smolak et al.|ACS Pharmacology & Translational Science|2024Cited by 8
Profile of NT-0527, a brain penetrant NLRP3 Inflammasome inhibitor suitable as an <i>in vivo</i> tool compound for neuroinflammatory disordersDavid Harrison, Alan P. Watt, Andy Billinton et al.|RSC Medicinal Chemistry|2025Cited by 3